Tagged with Phytopharmaceuticals

Andy Suter – CEO, A. Vogel

Switzerland Andy Suter – CEO, A. Vogel

Switzerland A. Vogel CEO Dr Andy Suter outlines the Swiss herbal medicine market leader’s expansion in recent years, why it is prioritising R&D more than ever, and how the COVID-19 pandemic has created a renewed focus on phytopharmaceuticals and preventive medicine. There is a segment of people looking to take…

Susanne Caspar – CEO, Linnea

Switzerland Susanne Caspar – CEO, Linnea

Switzerland Susanne Caspar, CEO at Swiss natural API producer Linnea, talks about her first few months in the company, the pharmaceutical industry’s growing embrace of natural ingredients, and why Linnea has made the move into cannabis API production. 2020 was defined by an increase in demand for dietary supplements because…

Georg Boonen – CEO, Max Zeller

Switzerland Georg Boonen – CEO, Max Zeller

Switzerland Georg Boonen, CEO of Switzerland’s leading phytopharmaceutical player Max Zeller, discusses the company’s expanded market position at home and abroad, how COVID-19 and a reconsideration of preventive healthcare could be an inflection point for phytopharma, and what keeps him motivated after 22 years at the firm. COVID has led…

Interview: Chin Chun Lin – Chairman, Taiwan Leader Biotech Corp., Taiwan

Taiwan Interview: Chin Chun Lin – Chairman, Taiwan Leader Biotech Corp., Taiwan

Taiwan Chin Chun Lin, chairman of Taiwan Leader Biotech Corp., discusses the importance of herbal medicine for preventive healthcare, and shares valuable insights into Taiwan Leader Biotech Corp., a leading company in medicinal fungus, that established brand recognition through balancing social, economic and environmental perspectives while promoting the importance of the…

Interview: Peter Gmünder – CEO, Bioforce AG, Switzerland

Switzerland Interview: Peter Gmünder – CEO, Bioforce AG, Switzerland

Switzerland With a recent clinical trial showing one of Bioforce’s Echinacea products to be non-inferior to the gold standard allopathic treatment Tamiflu, CEO Peter Gmünder is working to continue the work of Swiss phytopharmaceuticals pioneer Alfred Vogel by providing the highest quality natural remedies made using only fresh herbs if possible.…

Interview: Georg Boonen – CEO, Max Zeller, Switzerland

Switzerland Interview: Georg Boonen – CEO, Max Zeller, Switzerland

Switzerland The CEO of Max Zeller, a Swiss Phytopharmaceutical company, highlights the immense benefits his products have and furthermore discusses the company’s internationalization strategy. Mr Boonen, you joined Max Zeller in June 1999 and have spent almost all your professional career here. How have you seen the company evolve over time…

Other Topics

India

M&A

European Biotech

Cell & Gene Therapy

R&D Section Page